Literature DB >> 26769057

Role of MicroRNAs in NAFLD/NASH.

Gyongyi Szabo1, Timea Csak2,3.   

Abstract

MicroRNAs (miRNAs) are highly conserved, small, 18-25 nucleotide, non-coding RNAs that regulate gene expression at the post-transcriptional level. Each miRNA can regulate hundreds of target genes, and vice versa each target gene can be regulated by numerous miRNAs, suggesting a very complex network and explaining how miRNAs play pivotal roles in fine-tuning essentially all biological processes in all cell types in the liver. Here, we summarize the current knowledge on the role of miRNAs in the pathogenesis and diagnosis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with an outlook to the broader aspects of metabolic syndrome. Furthermore, we discuss the role of miRNAs as potential biomarkers and therapeutic targets in NAFLD/NASH.

Entities:  

Keywords:  MicroRNAs; NAFLD; NASH

Mesh:

Substances:

Year:  2016        PMID: 26769057     DOI: 10.1007/s10620-015-4002-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  140 in total

1.  Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology.

Authors:  Kathleen E Corey; Joseph Misdraji; Lou Gelrud; Lindsay Y King; Hui Zheng; Atul Malhotra; Raymond T Chung
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

Review 2.  MicroRNAs in kidney physiology and disease.

Authors:  Piera Trionfini; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-11-11       Impact factor: 28.314

3.  MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice.

Authors:  Angela Dolganiuc; Jan Petrasek; Karen Kodys; Donna Catalano; Pranoti Mandrekar; Arumugam Velayudham; Gyongyi Szabo
Journal:  Alcohol Clin Exp Res       Date:  2009-07-01       Impact factor: 3.455

4.  A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation.

Authors:  Guoqing Zhuang; Cong Meng; Xin Guo; Patali S Cheruku; Lei Shi; Hang Xu; Honggui Li; Gang Wang; Ashley R Evans; Stephen Safe; Chaodong Wu; Beiyan Zhou
Journal:  Circulation       Date:  2012-05-11       Impact factor: 29.690

5.  Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.

Authors:  Wonhee Hur; Joon Ho Lee; Sung Woo Kim; Jung-Hee Kim; Si Hyun Bae; Minhyung Kim; Daehee Hwang; Young Seok Kim; Taesun Park; Soo-Jong Um; Byoung-Joon Song; Seung Kew Yoon
Journal:  Int J Biochem Cell Biol       Date:  2015-05-07       Impact factor: 5.085

6.  Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.

Authors:  Yuki Kita; Toshinari Takamura; Hirofumi Misu; Tsuguhito Ota; Seiichiro Kurita; Yumie Takeshita; Masafumi Uno; Naoto Matsuzawa-Nagata; Ken-Ichiro Kato; Hitoshi Ando; Akio Fujimura; Koji Hayashi; Toru Kimura; Yinhua Ni; Toshiki Otoda; Ken-ichi Miyamoto; Yoh Zen; Yasuni Nakanuma; Shuichi Kaneko
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

7.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

8.  Biodistribution and function of extracellular miRNA-155 in mice.

Authors:  Shashi Bala; Timea Csak; Fatemeh Momen-Heravi; Dora Lippai; Karen Kodys; Donna Catalano; Abhishek Satishchandran; Victor Ambros; Gyongyi Szabo
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

Review 9.  MicroRNAs Related to Polycystic Ovary Syndrome (PCOS).

Authors:  Anja Elaine Sørensen; Marie Louise Wissing; Sofia Salö; Anne Lis Mikkelsen Englund; Louise Torp Dalgaard
Journal:  Genes (Basel)       Date:  2014-08-25       Impact factor: 4.096

10.  MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.

Authors:  Akiko Katsura; Asahiro Morishita; Hisakazu Iwama; Joji Tani; Teppei Sakamoto; Miwa Tatsuta; Yuka Toyota; Koji Fujita; Kiyohito Kato; Emiko Maeda; Takako Nomura; Hisaaki Miyoshi; Hirohito Yoneyama; Takashi Himoto; Shintaro Fujiwara; Hideki Kobara; Hirohito Mori; Toshiro Niki; Masafumi Ono; Mitsuomi Hirashima; Tsutomu Masaki
Journal:  Int J Mol Med       Date:  2015-02-06       Impact factor: 4.101

View more
  27 in total

1.  Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.

Authors:  André L Simão; Marta B Afonso; Pedro M Rodrigues; Margarida Gama-Carvalho; Mariana V Machado; Helena Cortez-Pinto; Cecília M P Rodrigues; Rui E Castro
Journal:  J Mol Med (Berl)       Date:  2019-05-28       Impact factor: 4.599

2.  Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Authors:  Rohitash Jamwal; Suzanne M de la Monte; Ken Ogasawara; Sravani Adusumalli; Benjamin B Barlock; Fatemeh Akhlaghi
Journal:  Mol Pharm       Date:  2018-06-11       Impact factor: 4.939

Review 3.  MicroRNAs and liver disease.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Mari Yamagami; Motoko Ohno; Akemi Takata; Chikako Shibata; Rei Ishibashi; Kazuhiko Koike
Journal:  J Hum Genet       Date:  2016-05-26       Impact factor: 3.172

4.  Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH.

Authors:  Shashi Bala; Michal Ganz; Mrigya Babuta; Yuan Zhuang; Timea Csak; Charles D Calenda; Gyongyi Szabo
Journal:  Lab Invest       Date:  2021-08-27       Impact factor: 5.502

Review 5.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

Review 6.  Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Authors:  Peter Willeit; Philipp Skroblin; Stefan Kiechl; Carlos Fernández-Hernando; Manuel Mayr
Journal:  Eur Heart J       Date:  2016-04-20       Impact factor: 29.983

Review 7.  miRNAs in non-alcoholic fatty liver disease.

Authors:  Zhen He; Cheng Hu; Weiping Jia
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

8.  The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice.

Authors:  Minjuan Ma; Rui Duan; Lulu Shen; Mengting Liu; Yaya Ji; Hao Zhou; Changxian Li; Tingming Liang; Xiangcheng Li; Li Guo
Journal:  J Lipid Res       Date:  2020-03-30       Impact factor: 5.922

9.  Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Authors:  Rebeca Escutia-Gutiérrez; J Samael Rodríguez-Sanabria; C Alejandra Monraz-Méndez; Jesús García-Bañuelos; Arturo Santos-García; Ana Sandoval-Rodríguez; Juan Armendáriz-Borunda
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

10.  Pathogenesis of NASH: The Impact of Multiple Pathways.

Authors:  Mazen Noureddin; Arun J Sanyal
Journal:  Curr Hepatol Rep       Date:  2018-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.